S100A7 and cancer: Exploration of the underlying molecular mechanisms demonstrated that intracellular S100A7 binds to JAB1 to promote the activation of the cancer‐associated AKT, ERK, and NF‐kB signaling pathways, thereby promoting ESCC progression.